Regulatory role of E3 ubiquitin ligases in normal B lymphopoiesis and B-cell malignancies.
暂无分享,去创建一个
[1] Li Yang,et al. E3 ubiquitin ligase neural precursor cell‐expressed developmentally downregulated gene 4 motivates FOXA1 ubiquitination and restrains proliferation of diffuse large B‐cell lymphoma cells via the Wnt/β‐Catenin pathway , 2023, Cell biology international.
[2] R. Bonasio,et al. DLBCL associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemo-resistance. , 2023, Blood.
[3] M. Kreft,et al. Huwe1 supports B-cell development, B-cell-dependent immunity, somatic hypermutation and class switch recombination by regulating proliferation , 2023, Frontiers in Immunology.
[4] Jeong-Ok Lee,et al. Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma , 2022, Journal of Cancer.
[5] Wei Yang,et al. Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma , 2022, Journal of translational medicine.
[6] Zhengsheng Wu,et al. LncRNA FIRRE stimulates PTBP1‐induced Smurf2 decay, stabilizes B‐cell receptor, and promotes the development of diffuse large B‐cell lymphoma , 2022, Hematological oncology.
[7] M. Safa,et al. Inhibition of Skp2 enhances doxorubicin‐induced cell death in B cell precursor acute lymphoblastic leukemia , 2022, Cell biology international.
[8] R. Gartenhaus,et al. PARK2 regulates eIF4B-driven lymphomagenesis. , 2022, Molecular cancer research : MCR.
[9] M. Renna,et al. IBtkα Activates the β-Catenin-Dependent Transcription of MYC through Ubiquitylation and Proteasomal Degradation of GSK3β in Cancerous B Cells , 2022, International journal of molecular sciences.
[10] Michael L. Wang,et al. Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo , 2021, Blood advances.
[11] L. Staudt,et al. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. , 2021, Blood advances.
[12] Lunquan Sun,et al. Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration , 2021, Journal of immunology research.
[13] C. Fontanillo,et al. Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen. , 2021, Blood advances.
[14] R. Kuiper,et al. Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma , 2021, Familial Cancer.
[15] Zhenyu Li,et al. Fbw7 Inhibits the Progression of Activated B-Cell Like Diffuse Large B-Cell Lymphoma by Targeting the Positive Feedback Loop of the LDHA/lactate/miR-223 Axis , 2020, Frontiers in Oncology.
[16] Xu Wang,et al. MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis. , 2020, Blood.
[17] C. Goodnow,et al. Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice , 2020, bioRxiv.
[18] K. Elenitoba-Johnson,et al. FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells , 2020, Cancer Research.
[19] Michael R. Green,et al. E3 Ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells. , 2020, Blood.
[20] L. Staudt,et al. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14 , 2020, Proceedings of the National Academy of Sciences.
[21] Jie Zhu,et al. CRL3–SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling , 2019, Leukemia.
[22] Qiaojun He,et al. Kelch-like proteins: physiological functions and relationships with diseases. , 2019, Pharmacological research.
[23] J. Gribben,et al. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation , 2019, Cell reports.
[24] Yan Li,et al. The E3 ubiquitin ligase Itch is required for B-cell development , 2019, Scientific Reports.
[25] J. Doench,et al. CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation , 2019, Cell reports.
[26] Bochra Zidi,et al. TP53INP1 deficiency maintains murine B lymphopoiesis in aged bone marrow through redox-controlled IL-7R/STAT5 signaling , 2018, Proceedings of the National Academy of Sciences.
[27] H. Eibel,et al. BAFF and BAFF-Receptor in B Cell Selection and Survival , 2018, Front. Immunol..
[28] Kou-Juey Wu,et al. Ubiquitination by HUWE1 in tumorigenesis and beyond , 2018, Journal of Biomedical Science.
[29] Yaofeng Zhao,et al. Kelch-like protein 14 promotes B-1a but suppresses B-1b cell development , 2018, International immunology.
[30] Jianxun Song,et al. The endoplasmic reticulum–resident E3 ubiquitin ligase Hrd1 controls a critical checkpoint in B cell development in mice , 2018, The Journal of Biological Chemistry.
[31] K. Young,et al. MYD88 L265P Mutation in Lymphoid Malignancies. , 2018, Cancer research.
[32] Michael R. Green,et al. Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor Roquin2 , 2018, Nature Cell Biology.
[33] M. Mallardo,et al. The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis , 2018, Cell Death & Disease.
[34] B. Bertocci,et al. Klhl6 Deficiency Impairs Transitional B Cell Survival and Differentiation , 2017, The Journal of Immunology.
[35] D. Vaux,et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. , 2017, The Journal of Biological Chemistry.
[36] Su Yao,et al. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation , 2017, Journal of Experimental & Clinical Cancer Research.
[37] S. Miyamoto,et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma , 2016, Oncogene.
[38] Sohee Oh,et al. PELI1 expression is correlated with MYC and BCL6 expression and associated with poor prognosis in diffuse large B-cell lymphoma , 2016, Modern Pathology.
[39] E. Wolf,et al. The ubiquitin ligase HUWE1 regulates hematopoietic stem cell maintenance and lymphoid commitment , 2016, Nature immunology.
[40] K. Basso,et al. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. , 2016, Blood.
[41] C. K. Watts,et al. Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer , 2015, Molecular Cancer Research.
[42] L. Staudt,et al. B-cell receptor signaling in diffuse large B-cell lymphoma. , 2015, Seminars in hematology.
[43] L. Staudt,et al. Protein ubiquitination in lymphoid malignancies , 2015, Immunological reviews.
[44] Ji-Eun Kim,et al. Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. , 2014, The Journal of clinical investigation.
[45] V. Pant,et al. Limiting the power of p53 through the ubiquitin proteasome pathway , 2014, Genes & development.
[46] Rudolf Grosschedl,et al. The regulatory network of B-cell differentiation: a focused view of early B-cell factor 1 function , 2014, Immunological reviews.
[47] K. Tarte,et al. A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells. , 2014, Blood.
[48] K. Iwai,et al. Mechanism Underlying IκB Kinase Activation Mediated by the Linear Ubiquitin Chain Assembly Complex , 2014, Molecular and Cellular Biology.
[49] P. Moynagh. The roles of Pellino E3 ubiquitin ligases in immunity , 2014, Nature Reviews Immunology.
[50] W. Gu,et al. Homeostatic defects in B cells deficient in the E3 ubiquitin ligase ARF-BP1 are restored by enhanced expression of MYC. , 2013, Leukemia research.
[51] Charusheila Ramkumar,et al. Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1 , 2013, Nature Communications.
[52] Xiao-Ming Yin,et al. The reciprocal roles of PARK2 and mitofusins in mitophagy and mitochondrial spheroid formation , 2013, Autophagy.
[53] Bodo Grimbacher,et al. B-cell biology and development. , 2013, The Journal of allergy and clinical immunology.
[54] L. Staudt,et al. Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma , 2013, Proceedings of the National Academy of Sciences.
[55] Christian Langer,et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma , 2012, Nature Cell Biology.
[56] P. Fox,et al. Pellino 2 Is critical for Toll-like Receptor/Interleukin-1 Receptor (TLR/IL-1R)-mediated Post-transcriptional Control* , 2012, The Journal of Biological Chemistry.
[57] Charusheila Ramkumar,et al. Smurf2 regulates the senescence response and suppresses tumorigenesis in mice. , 2012, Cancer research.
[58] C. Paige,et al. The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. , 2012, Seminars in immunology.
[59] Bill B. Chen,et al. F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. , 2012, Blood.
[60] L. Staudt,et al. Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.
[61] A. Hoffmann,et al. Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma , 2012, Nature Cell Biology.
[62] T. Mak,et al. The E3 ubiquitin ligase Mule acts through the ATM–p53 axis to maintain B lymphocyte homeostasis , 2012, The Journal of experimental medicine.
[63] Michele Pagano,et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas , 2012, Nature.
[64] Yi Tang,et al. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20 , 2011, Nature Medicine.
[65] W. Guo,et al. Genome‐wide copy number analyses identified novel cancer genes in hepatocellular carcinoma , 2011, Hepatology.
[66] Anthony W. Purcell,et al. Linear ubiquitination prevents inflammation and regulates immune signalling , 2011, Nature.
[67] A. Ma,et al. Ubiquitin makes its mark on immune regulation. , 2010, Immunity.
[68] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[69] K. Okkenhaug,et al. The PI3K Isoforms p110α and p110δ Are Essential for Pre–B Cell Receptor Signaling and B Cell Development , 2010, Science Signaling.
[70] J. Lötvall,et al. B Cells: From Early Development to Regulating Allergic Diseases , 2010, Archivum Immunologiae et Therapiae Experimentalis.
[71] A. Strasser,et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development , 2010, Nature Immunology.
[72] G. D. Gatta,et al. Hematopoietic Stem Cell Differentiation Regulated by a Single Ubiquitin Ligase: Substrate Complex , 2009, Nature Immunology.
[73] D. Rotin,et al. Physiological functions of the HECT family of ubiquitin ligases , 2009, Nature Reviews Molecular Cell Biology.
[74] M. Reth,et al. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling , 2009, Nature Reviews Immunology.
[75] S. Akira,et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation , 2009, Nature Cell Biology.
[76] Carl W. Miller,et al. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. , 2008, Leukemia research.
[77] R. DePinho,et al. Distinct roles for Foxo1 at multiple stages of B cell differentiation , 2008, Nature Immunology.
[78] Linheng Li,et al. Self-renewal versus transformation: Fbxw7 deletion leads to stem cell activation and leukemogenesis. , 2008, Genes & development.
[79] T. Yamazaki,et al. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. , 2008, Blood.
[80] L. Hendershot,et al. Characterization of an ERAD pathway for nonglycosylated BiP substrates, which require Herp. , 2007, Molecular cell.
[81] P. Moynagh,et al. Kinase-active Interleukin-1 Receptor-associated Kinases Promote Polyubiquitination and Degradation of the Pellino Family , 2007, Journal of Biological Chemistry.
[82] R. Hardy,et al. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. , 2007, Immunity.
[83] M. Busslinger,et al. Distinct Promoters Mediate the Regulation of Ebf1 Gene Expression by Interleukin-7 and Pax5 , 2006, Molecular and Cellular Biology.
[84] Gabriel Pons,et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.
[85] P. Sicinski,et al. A unique function for cyclin D3 in early B cell development , 2006, Nature Immunology.
[86] Claudia Waskow,et al. The BTB-kelch Protein KLHL6 Is Involved in B-Lymphocyte Antigen Receptor Signaling and Germinal Center Formation , 2005, Molecular and Cellular Biology.
[87] Jun Qin,et al. ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor , 2005, Cell.
[88] U. Siebenlist,et al. Control of lymphocyte development by nuclear factor-κB , 2005, Nature Reviews Immunology.
[89] E. Lam,et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells , 2005, Oncogene.
[90] C. Elly,et al. Differential Regulation of the B Cell Receptor-mediated Signaling by the E3 Ubiquitin Ligase Cbl* , 2004, Journal of Biological Chemistry.
[91] C. Mackay,et al. B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells1 , 2004, The Journal of Immunology.
[92] H. Young,et al. Distinct Regions of the Interleukin-7 Receptor Regulate Different Bcl2 Family Members , 2004, Molecular and Cellular Biology.
[93] A. Kudo,et al. EBF‐regulating Pax5 transcription is enhanced by STAT5 in the early stage of B cells , 2003, European journal of immunology.
[94] T. Greiner,et al. Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.
[95] J. Weill,et al. Specific over-expression of deltex and a new Kelch-like protein in human germinal center B cells. , 2003, Molecular immunology.
[96] A. Sánchez-Aguilera,et al. Cell cycle deregulation in B-cell lymphomas. , 2003, Blood.
[97] J. Ihle,et al. Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110δ in Signaling by the B-Cell Receptor Complex , 2002, Molecular and Cellular Biology.
[98] E. Vigorito,et al. A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation , 2002, The Journal of experimental medicine.
[99] R. Gerstein,et al. The Earliest Step in B Lineage Differentiation from Common Lymphoid Progenitors Is Critically Dependent upon Interleukin 7 , 2002, The Journal of experimental medicine.
[100] Yun-Cai Liu,et al. Cbl and Cbl-b in T-cell regulation. , 2002, Trends in immunology.
[101] H. Fleming,et al. Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B cell transition via an ERK/MAP kinase-dependent pathway. , 2001, Immunity.
[102] W. Langdon,et al. Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.
[103] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[104] F. Alt,et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. , 1999, Science.
[105] A. Israël,et al. Regulation of IkappaBbeta degradation. Similarities to and differences from IkappaBalpha. , 1997, The Journal of biological chemistry.
[106] T. Kinoshita,et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.
[107] Hai Qi,et al. External signals regulate germinal center fate‐determining transcription factors in the A20 lymphoma cell line , 2018, Molecular immunology.